Kevin C. Mannix | Teva Pharmaceutical Industries Ltd. |
Kåre Schultz | Teva Pharmaceutical Industries Ltd. |
Michael McClellan | Teva Pharmaceutical Industries Ltd. |
Brendan O'Grady | Teva Pharmaceutical Industries Ltd. |
Liav Abraham | Citigroup Global Markets, Inc. (Broker) |
David Maris | Wells Fargo Securities LLC |
Jami Rubin | Goldman Sachs & Co. LLC |
Christopher Schott | JPMorgan Securities LLC |
Aharon Gal | Sanford C. Bernstein & Co. LLC |
Gregg Gilbert | Deutsche Bank Securities, Inc. |
Umer Raffat | Evercore Group LLC |
Elliot Wilbur | Raymond James & Associates, Inc. |
Irina R. Koffler | Mizuho Securities USA LLC |
Ladies and gentlemen, thank you for standing by and welcome to the Teva Pharmaceutical second quarter 2018 financial results call. At this time, all participants are in a listen-only mode. There will be a presentation, followed by a question-and-answer session. I must advise you the conference is being recorded today, Thursday, August 2, 2018. I would now like to turn the conference over to your first speaker today, Kevin Mannix, Senior Vice President, Head of Investor Relations.